Berger Financial Group, Inc
Position in REGN — Regeneron Pharmaceuticals, Inc.
CIK 1826136
Plymouth, MN
Position in REGN
as of Mar 31, 2026
· filed Apr 28, 2026
Position Value
$231,792
-$540 QoQ
Shares Held
300
-0.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
19 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Berger Financial Group, Inc holds $1,156,180 across 3 Biotechnology names.
All Filings in REGN
Export CSV
19 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $231,792 | 300 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $232,332 | 301 | Shares | Sole | 2026-01-27 | |
| 2025-03-31 | $239,104 | 377 | Shares | Sole | 2025-05-12 | |
| 2024-12-31 | $274,247 | 385 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $411,034 | 391 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $404,646 | 385 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $362,858 | 377 | Shares | Sole | 2024-04-16 | |
| 2023-12-31 | $288,957 | 329 | Shares | Sole | 2024-02-07 | |
| 2023-09-30 | $273,222 | 332 | Shares | Sole | 2023-11-03 | |
| 2023-06-30 | $252,926 | 352 | Shares | Sole | 2023-08-10 | |
| 2023-03-31 | $274,437 | 334 | Shares | Sole | 2023-04-24 | |
| 2022-12-31 | $297,975 | 413 | Shares | Sole | 2023-01-30 | |
| 2022-09-30 | $278,992 | 405 | Shares | Sole | 2022-10-27 | |
| 2022-06-30 | $260,097 | 440 | Shares | Sole | 2022-08-08 | |
| 2022-03-31 | $316,384 | 453 | Shares | Sole | 2022-05-10 | |
| 2021-12-31 | $5,140,572 | 8,140 | Shares | Sole | 2022-01-26 | |
| 2021-09-30 | $4,788,789 | 7,913 | Shares | Sole | 2021-10-28 | |
| 2021-06-30 | $4,454,356 | 7,975 | Shares | Sole | 2021-07-29 | |
| 2021-03-31 | $3,584,508 | 7,576 | Shares | Sole | 2021-05-12 | |
| No filing history on record for this holder in this stock. | ||||||